Sensei Biotherapeutics Inc (FRA:407)
€ 0.367 0 (0%) Market Cap: 10.90 Mil Enterprise Value: -29.88 Mil PE Ratio: 0 PB Ratio: 0.26 GF Score: 29/100

Sensei Biotherapeutics Inc at Canaccord Genuity Growth Conference Transcript

Aug 09, 2023 / 01:30PM GMT
Release Date Price: €1.07 (+0.56%)
John Newman
Canaccord Genuity Group Inc. - Analyst

Hey. Good morning, everybody, and thank you very much for joining us at the 43rd Annual Canaccord Genuity Growth Conference here in sunny Boston today. I'm John Newman and one of the biotech analysts here at the firm. We're very excited to have Sensei with us today. Joining us is the Chief Scientific Officer, Edward van der Horst. Welcome, Edward.

So wondering if you could start off talking about some of the key challenges for immuno-oncology in treating solid tumors, though it's kind of a broad question and also the approaches that Sensei brings to that challenge. Thanks.

Edward van der Horst
Sensei Biotherapeutics, Inc. - Chief Scientific Officer

Sure. Good morning, everybody. Yeah, this is -- there is the question is (technical difficulty) targeting solid tumors (technical difficulty) act for a second what (technical difficulty) its cancer and compared to other indications or disease areas. So if you compare that, say, cancer to cardiovascular, then abstract that a little bit. Cardiovascular

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot